Drugs for Hypophosphatemic Rickets, X-Linked Recessive (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 48)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cholecalciferol |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
67-97-0, 1406-16-2 |
5280795 10883523 |
Synonyms:
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,4E,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3BETA,Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
(3Î’,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
3-BETA,Z,7E-9,10-SECOCHOLESTR-5,7,10(19)-TRIEN-3-OL
7-DEHYDROCHOLESTEROL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
ACCRETE D3
ACIFEROL D3
ACTIVATED
Activated 7-dehydrocholesterol
ADCAL-D3
ARACHITOL
AVITICOL
BIOLIFE VITAMIN D3
BIO-VITAMIN D3
CACIT D3
CALCEOS
CALCICHEW D3
CALCICHEW D3 FTE
CALCICHEW D3 ONCE DAILY
CALCI-D
Calciferol
Calciol
CALDRINK D3
CALFOVIT D3
CC
Cholecalciferol
CHOLECALCIFEROL D3
Cholecalciferols
Cholecalciferolum
COLECAL D3
Colecalciferol
Colecalciferolum
COLEKAL-D3
COLEVIT D3
CUBICOLE D3
D3 LEMON MELTS
D3-50
D3-VIGANTOL
DEKRISTOL
DELSTEROL
Delta-D
DEPARAL
DESUNIN
DEVARON
Dihydrocholesterol
DLUX 400
D-MAX
D-TRACETTEN
|
D-VIT3
EBIVIT
E-D3
EVACAL D3
FERACOL
FULTIUM DAILY D3
FULTIUM-D3
GRANUVIT D3
HUX D3
INVITA D3
ISO D3
KORA LIQUID
MICRO-DEE
NATECAL D3
NATURE'S REMEDY VITAMIN D3
NEO-D
NPHD3
NSC-375571
Oleovitamin D3
OSTEOCAPS D3
PLENACHOL
PRO D3
PRO D3 FOLIC
PRO D3 FORTE
PROVITINA
QUINTOX
RICKETON
ROYALVIT D3
STEXEROL-D3
STIVIT-D3
SUNVIT-D3 1,000
SUNVIT-D3 10,000
SUNVIT-D3 2,000
SUNVIT-D3 20,000
SUNVIT-D3 3,000
SUNVIT-D3 400
SUNVIT-D3 5,000
SUNVIT-D3 50,000
SUNVIT-D3 800
SYNERVIT-D3
THEICAL D-3
THORENS
TRIVITAN
VIDDE-3-HYDROSOL
VI-DE3
VIDEKHOL
VIGANTOL
VIGANTOLETTEN
VIGANTOLETTEN 500
VIGORSAN
VIT D3 STREULI
VITA-D3
VITAMIN D
Vitamin D 3
VITAMIN D ASSAY SYSTEM SUITABILITY
Vitamin D NOS
Vitamin D, unspecified form
Vitamin D3
Vitamin D-3
VITINC DAN-DEE-3
ZYMAD
δ-D
|
|
2 |
|
Calcitriol |
Approved, Nutraceutical |
Phase 4 |
|
32222-06-3 |
5280453 |
Synonyms:
(1a,3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1R,3S,5Z)-5-{2-[(1R,3AS,4E,7AR)-1-[(2R)-6-HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXANE-1,3-DIOL
(1S,3R,5Z,7E)-9,10-Seco-5,7,10(19)-cholestatriene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol
(1Α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol
(5Z,7E)-(1S,3R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
1 alpha, 25 Dihydroxy 20 epi vitamin D3
1 alpha, 25-Dihydroxy-20-epi-vitamin D3
1 alpha,25 Dihydroxycholecalciferol
1 alpha,25 Dihydroxyvitamin D3
1 alpha,25-Dihydroxycholecalciferol
1 alpha,25-Dihydroxyvitamin D3
1,25 Dihydroxy 20 epi vitamin D3
1,25 Dihydroxycholecalciferol
1,25 Dihydroxyvitamin D3
1,25(OH)2-20EPi-D3
1,25-DHCC
1,25-Dihydroxy-20-epi-vitamin D3
1,25-Dihydroxycholecalciferol
1,25-Dihydroxyvitamin D
1,25-Dihydroxyvitamin D3
1a,25(OH)2D3
1a,25-(OH)2D3
1a,25-Dihydroxycholecalciferol
1a,25-Dihydroxyvitamin D3
1a,25-Dihydroxyvitamin D3 / 1a,25-dihydroxycholecalciferol / calcitriol
1-a-25-Dihydroxyvitamin D3
1alpha,25(OH)2D3
1alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D3
1-alpha,25-Dihydroxyvitamin D3
1-alpha-25-Dihydroxyvitamin D3
1Α,25(OH)2D3
1Α,25-dihydroxycholecalciferol
1Α,25-dihydroxyvitamin D3
1Α,25-dihydroxyvitamin D3 / 1α,25-dihydroxycholecalciferol / calcitriol
1-Α-25-dihydroxyvitamin D3
20 Epi 1alpha,25 dihydroxycholecaliferol
20-Epi-1alpha,25-dihydroxycholecaliferol
25-Dihydroxycholecalciferol
5-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
Abbott brand OF calcitriol
alpha,25-Dihydroxyvitamin D3, 1
Alphapharm brand OF calcitriol
Bocatriol
Calcijex
Calcijex®|calcitriol|Rocaltrol®
|
Calcitriol
Calcitriol abbott brand
Calcitriol alphapharm brand
Calcitriol cryopharma brand
Calcitriol galderma brand
Calcitriol gry brand
Calcitriol jenapharm brand
Calcitriol kyramed
Calcitriol kyramed brand
Calcitriol leo brand
Calcitriol medice brand
Calcitriol nefro
Calcitriol renacare brand
Calcitriol roche brand
Calcitriol-nefro
CalcitriolNefro
Calcitriolum
Cryopharma brand OF calcitriol
D3, 1 alpha,25-Dihydroxyvitamin
D3, 1,25-Dihydroxy-20-epi-vitamin
D3, 1,25-Dihydroxyvitamin
Decostriol
DIHYDROXYCHOLECALCIFEROL
DIHYDROXYVITAMIN D 3
Dihydroxyvitamin D3
Galderma brand OF calcitriol
Gry brand OF calcitriol
Hoffmann la roche brand OF calcitriol
Hoffmann-la roche brand OF calcitriol
Jenapharm brand OF calcitriol
KyraMed brand OF calcitriol
KyraMed, calcitriol
Leo brand OF calcitriol
Medice brand OF calcitriol
Osteotriol
RenaCare brand OF calcitriol
Renatriol
Ro 21-5535
RO-215535
RO-21-5535
Rocaltrol
Roche brand OF calcitriol
Silkis
Sitriol
Soltriol
Tirocal
Topitriol
Toptriol
VECTICAL
|
|
3 |
|
Antibodies, Monoclonal |
|
Phase 4 |
|
|
|
4 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
5 |
|
Vitamins |
|
Phase 4 |
|
|
|
6 |
|
Hormones |
|
Phase 4 |
|
|
|
7 |
|
Trace Elements |
|
Phase 4 |
|
|
|
8 |
|
Calciferol |
|
Phase 4 |
|
|
|
9 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
10 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
11 |
|
Micronutrients |
|
Phase 4 |
|
|
|
12 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
13 |
|
Parathyroid hormone |
Approved, Investigational |
Phase 3 |
|
9002-64-6 |
|
Synonyms:
ALX1-11
ALX-111
ALX-1-11
NPSP558
NPSP-558
Parathormone
Parathormone (human recombinant)
Parathyrin
PARATHYROID HORMONE
Parathyroid hormone (1-84) human recombinant
|
Parathyroid hormone (rDNA)
PAROIDIN
PREOTACT
PTH
PTH(1-84)
rhPTH
rhPTH(1-84)
rPTH
rPTH(1-84)
|
|
14 |
|
Sodium fluoride |
Approved |
Phase 3 |
|
7681-49-4 |
|
Synonyms:
Fluoride, sodium
Fluorides, sodium
Fluorinse
Fluoristat
Fluoristats
NaF
Ossin
|
Ossins
Procter and gamble brand OF sodium fluoride
Sodium fluoride
Sodium fluorides
Zymafluor
Zymafluors
|
|
15 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
16 |
|
Mitogens |
|
Phase 3 |
|
|
|
17 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
18 |
|
Antibodies |
|
Phase 3 |
|
|
|
19 |
|
Listerine |
|
Phase 3 |
|
|
|
20 |
|
Fluorides, Topical |
|
Phase 3 |
|
|
|
21 |
|
Fluorides |
|
Phase 3 |
|
|
|
22 |
|
Protective Agents |
|
Phase 3 |
|
|
|
23 |
|
Hormone Antagonists |
|
Phase 1, Phase 2 |
|
|
|
24 |
|
Immunoglobulins, Intravenous |
|
Phase 1, Phase 2 |
|
|
|
25 |
|
Immunoglobulin Fc Fragments |
|
Phase 1, Phase 2 |
|
|
|
26 |
|
Cinacalcet |
Approved |
Phase 1 |
|
226256-56-0 |
156419 |
Synonyms:
(R)-alpha-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
(R)-a-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
(R)-Α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
073, AMG
1493, KRN
alpha-Methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphar)-hydrochloride
AMG 073
AMG-073
AMG-073|Mimpara®|Sensipar®
|
CINACALCET
Cinacalcet hydrochloride
CNC
Hydrochloride, cinacalcet
KRN1493
KRN-1493
Mimpara
N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
Sensipar
|
|
27 |
|
Sevelamer |
Approved |
|
|
52757-95-6 |
3085017 |
Synonyms:
RENAGEL
RENVELA
Sevelamer
|
Sévélamer
Sevelamero
Sevelamerum
|
|
28 |
|
Sodium citrate |
Approved, Investigational |
|
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
29 |
|
Ferrous gluconate |
Approved |
|
|
299-29-6 |
|
Synonyms:
D-gluconic acid, iron(2+) salt (2:1)
Ferric Gluconate
Ferrous gluconate anhydrous
|
Iron(2+) gluconate (1:2)
Iron(II) gluconate, anhydrous
|
|
30 |
|
Iron |
Approved |
|
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
31 |
|
Salmon calcitonin |
Approved, Investigational |
|
|
47931-85-1 |
155817456 |
Synonyms:
CALCITONIN (SALMON SYNTHETIC)
Calcitonin salmon
CALCITONIN SALMON RECOMBINANT
Calcitonin, salmon
Calcitonina salmón sintética
|
Calcitonin-salmon
CT (salmon)|Miacalcin®
FORTICAL
Recombinant salmon calcitonin
Salmon calcitonin
|
|
32 |
|
Alfacalcidol |
Approved, Nutraceutical |
|
|
41294-56-8 |
5282181 |
Synonyms:
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1a,3b-diol
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1α,3β-diol
1 alpha-Hydroxycholecalciferol
1 alpha-Hydroxyvitamin D3
1a-Hydroxycholecalciferol
1a-Hydroxyvitamin D3
1a-Hydroxy-vitamin D3
1a-Hydroxyvitamin D3 / 1a-hydroxycholecalciferol
1alpha-Hydroxycholecalciferol
1alpha-Hydroxyvitamin D3
1alpha-Hydroxy-vitamin D3
1alpha-OHD3
1-alpha-Oxycholecalciferol
1-Hydroxycholecalciferol
1-Hydroxycholecalciferol, (1alpha,3alpha-(5Z,7E))-isomer
1-Hydroxycholecalciferol, (1beta)-(5Z)-isomer
1-Hydroxycholecalciferol, (1beta,3beta-(5E,7E))-isomer
1-Hydroxycholecalciferol, aluminum salt
1Α-hydroxycholecalciferol
|
1Α-hydroxyvitamin D3
1Α-hydroxy-vitamin D3
1Α-hydroxyvitamin D3 / 1α-hydroxycholecalciferol
9,10-Secocholesta-5,7,10(19)-triene-1a,3b-diol
9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta-diol
9,10-Secocholesta-5,7,10(19)-triene-1α,3β-diol
Alfacalcidol
Alfacalcidolum
AlfaD
Alphacalcidol
Alsiodol
Bondiol
Doss brand OF alfacalcidol
Eenalfadrie
EinsAlpha
Etalpha
Oksidevit
One-Alpha
Un-alfa
|
|
33 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
|
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
34 |
|
Calcitonin gene-related peptide |
Investigational |
|
|
83652-28-2 |
91976570 |
Synonyms:
2-{[2-({6-amino-2-[(2-{[2-({2-[(2-{[2-({[1-(2-{[2-({2-[(2-{[6-amino-2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[({19-[(2-amino-1-hydroxypropylidene)amino]-16-(carboxymethyl)-6,9,12,15,18-pentahydroxy-7,13-bis(1-hydroxyethyl)-10-methyl-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-4-yl}(hydroxy)methylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(1H-imidazol-5-yl)propylidene)amino]-5-carbamimidamido-1-hydroxypentylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxypropylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxy-4-methylpentylidene)amino]-1,3-dihydroxypropylidene}amino)-5-carbamimidamido-1-hydroxypentylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxy-3-methylbutylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxyhexylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene)amino]-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene}amino)-1-hydroxy-3-phenylpropylidene]amino}-3-methylbutanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxyethylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxyhexylidene}amino)-1-hydroxypropylidene]amino}-3-phenylpropanoate
Calcitonin gene related peptide
Calcitonin-gene-related peptide
|
|
|
35 |
|
Hydroxycholecalciferols |
|
|
|
|
|
36 |
|
Chelating Agents |
|
|
|
|
|
37 |
|
Citrate |
|
|
|
|
|
38 |
|
Iron Supplement |
|
|
|
|
|
39 |
|
Hematinics |
|
|
|
|
|
40 |
|
Calcitonin |
|
|
|
|
|
Synonyms:
4-{[1-({1-[(5-amino-1-{[1-({1-[(1-{[1-(2-{[4-carbamimidamido-1-({2-hydroxy-1-[(1-{[2-hydroxy-1-({[(2-hydroxy-1-{[({3-hydroxy-1-[2-(C-hydroxycarbonimidoyl)pyrrolidin-1-yl]-1-oxobutan-2-yl}-C-hydroxycarbonimidoyl)methyl]-C-hydroxycarbonimidoyl}ethyl)-C-hydroxycarbonimidoyl]methyl}-C-hydroxycarbonimidoyl)propyl]-C-hydroxycarbonimidoyl}-2-(C-hydroxycarbonimidoyl)ethyl)-C-hydroxycarbonimidoyl]propyl}-C-hydroxycarbonimidoyl)butyl]-C-hydroxycarbonimidoyl}pyrrolidin-1-yl)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-C-hydroxycarbonimidoyl}-2-hydroxypropyl)-C-hydroxycarbonimidoyl]-3-(C-hydroxycarbonimidoyl)propyl}-C-hydroxycarbonimidoyl)-3-methylbutyl]-C-hydroxycarbonimidoyl}pentyl)-C-hydroxycarbonimidoyl]-2-(1H-imidazol-5-yl)ethyl}-C-hydroxycarbonimidoyl)-3-methylbutyl]-C-hydroxycarbonimidoyl}-4-({2-[(2-{[2-({6-amino-2-[(2-{[2-({2-[({22-amino-6,9,12,15,18,21-hexahydroxy-16-[(C-hydroxycarbonimidoyl)methyl]-7-(1-hydroxyethyl)-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosa-5,8,11,14,17,20-hexaen-4-yl}(hydroxy)methylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxyhexylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene}amino)butanoate
Calcihexal
Calcimar
CALCITARE
CALCITONIN
Calcitonin salmon
CALSYNAR
Cibacalcin
Forcaltonin
|
Fortical
Miacalcic
Miacalcin
Recombinant salmon calcitonin
Salcatonin
Salmon calcitonin
Salmon calcitonin (1-32)
Synthetic salmon calcitonin
|
|
41 |
|
Vasodilator Agents |
|
|
|
|
|
42 |
|
Katacalcin |
|
|
|
|
16172926 |
43 |
|
Neurotransmitter Agents |
|
|
|
|
|
44 |
|
Methacholine Chloride |
|
|
|
|
|
Synonyms:
|
45 |
|
Respiratory System Agents |
|
|
|
|
|
46 |
|
Muscarinic Agonists |
|
|
|
|
|
47 |
|
Cholinergic Agents |
|
|
|
|
|
48 |
|
Dihydroxycholecalciferols |
|
Early Phase 1 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 54)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
12-months of Treatment With Burosumab in Children and Adolescents With X-linked Hypophosphatemia: a Prospective Longitudinal Cohort Study |
Unknown status |
NCT04419363 |
Phase 4 |
Burosumab Injection |
2 |
An Open Label Trial to Assess the Safety and Efficacy of KRN23, an Investigational Antibody to FGF23, in a Single Pediatric Patient With Epidermal Nevus Syndrome (ENS) and Associated Hypophosphatemic Rickets |
Completed |
NCT04320316 |
Phase 4 |
Crysvita (burosumab-twza) Treatment |
3 |
Examining the Effect of Burosumab on Muscle Function Using MR Spectroscopy |
Completed |
NCT04146935 |
Phase 4 |
Burosumab Injection [Crysvita] |
4 |
An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Chinese Patients With X-linked Hypophosphatemic Rickets/Osteomalacia (XLH) |
Recruiting |
NCT04842032 |
Phase 4 |
KRN23 |
5 |
An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With X-linked Hypophosphatemic Rickets/Osteomalacia |
Recruiting |
NCT04842019 |
Phase 4 |
KRN23 |
6 |
Comparing the Effectiveness of High or Low Dose of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia |
Recruiting |
NCT03820518 |
Phase 4 |
Calcitriol |
7 |
The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH) |
Completed |
NCT00417612 |
Phase 3 |
Paricalcitol |
8 |
A Phase 3 Long-term Extension Study of KRN23 in Patients With X-linked Hypophosphatemic Rickets/Osteomalacia and a Post-marketing Study of KRN23 Switched From the Phase 3 Long-term Extension Study |
Completed |
NCT04308096 |
Phase 3 |
KRN23 |
9 |
A Phase 3 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia and a Postmarketing Study of KRN23 Switched From the Phase 3 Trial |
Completed |
NCT03233126 |
Phase 3 |
KRN23 |
10 |
An Open Label Trial to Assess the Safety and Efficacy of Burosumab (KRN23), an Investigational Antibody to FGF23, in a Single Pediatric Patient With Epidermal Nevus Syndrome(ENS) and Associated Hypophosphatemic Rickets |
Completed |
NCT03581591 |
Phase 3 |
|
11 |
Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets |
Completed |
NCT01237288 |
Phase 3 |
Z-521 |
12 |
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH) |
Completed |
NCT03920072 |
Phase 3 |
Burosumab |
13 |
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) |
Completed |
NCT02537431 |
Phase 3 |
|
14 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH) |
Completed |
NCT02526160 |
Phase 3 |
|
15 |
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH) |
Completed |
NCT02915705 |
Phase 3 |
Oral Phosphate Supplement;active vitamin D |
16 |
An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With Xlinked Hypophosphatemia (XLH) in GERmany - BurGER |
Active, not recruiting |
NCT04695860 |
Phase 3 |
Burosumab |
17 |
Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia: a Multicentre Randomized Controlled Trial |
Not yet recruiting |
NCT04872907 |
Phase 3 |
flowable composite |
18 |
Proposition Pour un Traitement Par Hormone de Croissance Des Enfants Atteints de Rachitisme Hypophosphatemique Familial |
Completed |
NCT02720770 |
Phase 1, Phase 2 |
norditropine simplex |
19 |
An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) |
Completed |
NCT02750618 |
Phase 2 |
|
20 |
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) |
Completed |
NCT02312687 |
Phase 2 |
|
21 |
A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH) |
Completed |
NCT02163577 |
Phase 2 |
|
22 |
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia |
Completed |
NCT01340482 |
Phase 1, Phase 2 |
KRN23 |
23 |
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia |
Completed |
NCT01571596 |
Phase 1, Phase 2 |
KRN23 |
24 |
A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults With ENPP1 Deficiency |
Recruiting |
NCT04686175 |
Phase 1, Phase 2 |
INZ-701 |
25 |
A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH) |
Active, not recruiting |
NCT04188964 |
Phase 1, Phase 2 |
Burosumab |
26 |
Effects of Growth Hormone Treatment on Body Proportions and Final Height Among Small Children With X-Linked Hypophosphatemic Rickets |
Unknown status |
NCT00473187 |
Phase 1 |
somatropin |
27 |
Effect of Calcimimetic (Cinacalcet) on Phosphate-Induced Hyperparathyroidism in Children With Hypophosphatemic Rickets |
Completed |
NCT00195936 |
Phase 1 |
Cinacalcet |
28 |
A Phase 1, Multicenter, Open-label, Sequential Dose-escalation, Single-dose Study to Assess the Safety and Tolerability of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia. |
Completed |
NCT02181764 |
Phase 1 |
KRN23 |
29 |
A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia |
Completed |
NCT00830674 |
Phase 1 |
Placebo;KRN23 |
30 |
The Natural History of Generalized Arterial Calcification of Infancy (GACI) With or Without Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2) or Pseudoxanthoma Elasticum (PXE) |
Unknown status |
NCT03758534 |
|
|
31 |
Hypophosphatemic Rickets in Norway |
Unknown status |
NCT01057186 |
|
Sevelamer |
32 |
Retrospective and Prospective Disease Progression and Quality of Life in X-linked Hypophosphatemia (XLH) |
Unknown status |
NCT04049877 |
|
|
33 |
Milk Products in the Treatment of Hypophosphatemic Rickets: A Randomised Crossover Trial |
Completed |
NCT03348644 |
|
|
34 |
Effect of Burosumab and 1-25 (OH) Vitamin D on Human Osteoclasts From Patients With Hypophosphatemic Rickets (HR) |
Completed |
NCT04184661 |
|
|
35 |
A Natural History Study of Patients With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2) |
Completed |
NCT03478839 |
|
|
36 |
Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot |
Completed |
NCT02233322 |
|
|
37 |
Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency Through the Eyes of Patients and Parents; Burden of Illness Perspectives From Patients and Parents Who Speak English, French or German |
Completed |
NCT04372446 |
|
|
38 |
Calcitonin for Treating X-linked Hypophosphatemia |
Completed |
NCT01652573 |
|
nasal salmon calcitonin;Saline Nasal Spray Placebo |
39 |
X-linked Hypophosphatemia and Carbohydrate and Lipid Metabolism: a Role for FGF21? |
Completed |
NCT03596554 |
|
|
40 |
Assessment Of Vitamin D Role In The Pathogenesis Of Asthma In Vitamin D Resistent Patients |
Completed |
NCT01578824 |
|
|
41 |
Interplay of FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP) |
Completed |
NCT03489993 |
|
|
42 |
Calcitriol Monotherapy for X-Linked Hypophosphatemia: Effects on Mineral Ions, Growth and Skeletal Parameters |
Recruiting |
NCT03748966 |
Early Phase 1 |
Calcitriol |
43 |
Effect of Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts From Patients Requiring Craniosynostosis Surgery for Idiopathic Reason or Due to Hypophosphatemic Rickets (HR) |
Recruiting |
NCT04159675 |
|
|
44 |
An International, Multicenter, Prospective, Longitudinal Observational Study for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia |
Recruiting |
NCT03745521 |
|
|
45 |
Characterising Pain, Quality of Life, Body Composition, Arterial Stiffness, Muscle Function, Bone Density and Geometry in Adult Persons With Hereditary Hypophosphatemia and Healthy Controls |
Recruiting |
NCT04273490 |
|
|
46 |
Dental Implants in Patients With X-linked Hypophosphatemia |
Recruiting |
NCT03879915 |
|
|
47 |
An Observational, Prospective, European, Multicentre, Mixed Methods Study to Describe the Lived Experience of X-Linked Hypophosphatemia (XLH) for Adolescents at End of Skeletal Growth |
Recruiting |
NCT05181839 |
|
Burosumab |
48 |
An International, Multicentre, Prospective, Non-interventional Observational Registry for Patients With X-Linked Hypophosphatemia (XLH) |
Recruiting |
NCT03193476 |
|
|
49 |
Identification of Longitudinal Burden of Disease and Functional Impairment in X-Linked Hypophosphatemia |
Recruiting |
NCT04946409 |
|
|
50 |
A UK Multicentre, Non-interventional, Observational, Health-Related Quality of Life Study for Children and Adolescents With X-linked Hypophosphataemia |
Recruiting |
NCT04819490 |
|
|
|